Restoring vision for patients with rare and severe ocular conditions
Claris Bio is focused on advancing meaningful therapies for patients who have historically had limited or no treatment options. With an initial focus on limbal stem cell deficiency (LSCD), we are developing the first pharmacologic approach designed to preserve and restore vision, moving beyond palliative care and toward lasting impact.
Learn More
Advancing a Disease-
Modifying Therapy
Advancing a Disease-
Modifying Therapy
CSB-001
We believe that our lead candidate, CSB-001, has the potential to transform the treatment of rare and severe corneal diseases by addressing the underlying drivers of vision loss. Leveraging the multi-modal activity of recombinant human hepatocyte growth factor (HGF), our approach promotes corneal epithelial regeneration while reducing inflammation and scarring, moving care beyond palliative management for patients with limited options.